CN101314031A - Preparation for improving osteotrophy - Google Patents
Preparation for improving osteotrophy Download PDFInfo
- Publication number
- CN101314031A CN101314031A CNA2008100586864A CN200810058686A CN101314031A CN 101314031 A CN101314031 A CN 101314031A CN A2008100586864 A CNA2008100586864 A CN A2008100586864A CN 200810058686 A CN200810058686 A CN 200810058686A CN 101314031 A CN101314031 A CN 101314031A
- Authority
- CN
- China
- Prior art keywords
- preparation
- osteotrophy
- adjuvant
- improves
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 50
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 25
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 239000002671 adjuvant Substances 0.000 claims description 20
- 229940071162 caseinate Drugs 0.000 claims description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229920003081 Povidone K 30 Polymers 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000007941 film coated tablet Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000007901 soft capsule Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 108010011485 Aspartame Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 229960003943 hypromellose Drugs 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 24
- 239000011575 calcium Substances 0.000 abstract description 24
- 229910052791 calcium Inorganic materials 0.000 abstract description 24
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 230000004097 bone metabolism Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 3
- 229940069978 calcium supplement Drugs 0.000 abstract 2
- 239000005018 casein Substances 0.000 abstract 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract 2
- 235000021240 caseins Nutrition 0.000 abstract 2
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 238000002156 mixing Methods 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000007908 dry granulation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- HBYOLNPZXLHVQA-UHFFFAOYSA-J dicalcium dicarbonate Chemical compound [Ca+2].[Ca+2].[O-]C([O-])=O.[O-]C([O-])=O HBYOLNPZXLHVQA-UHFFFAOYSA-J 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a preparation for improving osteotrophy, relating to a calcium supplement product, in particular to a calcium supplement preparation for improving the osteotrophy. The invention is mainly prepared from main materials of calcium carbonate and casein phosphopeptide. The main materials are prepared by weight portion: 10 to 60 portions of calcium carbonate, 1 portion of casein phosphopeptide and 0.1 to 250 portions of auxiliary materials. The formula of the invention is scientific and reasonable and has functions of directly supplementing calcium, promoting calcium absorption, reducing calcium loss, improving the osteotrophy and bone metabolism and increasing bone mineral density.
Description
Technical field
The present invention relates to a kind of product of replenishing the calcium, particularly a kind of calcium-supplementing preparation that improves osteotrophy.
Background technology
Nearly 99% calcareous being present in skeleton and the tooth in the human body, when calcium concentration was undesired in the body fluid, blood just can absorb calcium from skeleton, cause the loss of calcium in the skeleton, and calcareous loss will cause the generation of skeletal diseases.Avoid calcium loss, increase calcareous absorption and just become the important means that promotes bone health.Replenish the calcium in the market medicine and food variety is a lot, but because the environment that body is built calcium absorption is more single, makes calcium be difficult to absorb or absorb not exclusively.Some directly replenish the preparation of calcium, because absorption is bad, the calcium that is replenished is difficult for being absorbed, and causes a large amount of calcium losses on the contrary, cause the osteotrophy imbalance, very easily cause skeletal diseases because of calcium deficiency.
Goal of the invention
Purpose of the present invention is intended to overcome the defective of prior art, provides a kind of and can realize the bone density improving function, can directly replenish calcium, and can promote calcium absorption, reduces calcium loss, improves bone metabolism and improve the preparation of osteotrophy.
The preparation that improves osteotrophy of the present invention mainly is to be that primary raw material preparation gets by calcium carbonate, phosphopeptide caseinate, and its main components in percentage by weight is: calcium carbonate 10-60 part, 1 part of phosphopeptide caseinate, adjuvant 0.1-250 part.
The content of described calcium carbonate is greater than or equal to 80%.
Described calcium carbonate be animal shell or the chemical compound that obtains with existing method.
Described preparation is a kind of in tablet, film coated tablet, capsule, soft capsule, granule, the oral liquid.
Described adjuvant, the adjuvant of tablet, film coated tablet are microcrystalline Cellulose, 30 POVIDONE K 30 BP/USP 30, magnesium stearate, hypromellose.
Described adjuvant, the adjuvant of capsule be in starch, microcrystalline Cellulose, carboxymethylstach sodium, magnesium stearate, the Capsules more than two kinds or three kinds.
Described adjuvant, soft capsule adjuvant are gelatin, glycerol.
Described adjuvant, the adjuvant of granule are one or two or more kinds in sucrose, mannitol, the aspartame.
The preparation that improves osteotrophy of the present invention, its preparation method is:
A. under the normal temperature and pressure with calcium carbonate and phosphopeptide caseinate mix homogeneously;
B. add adjuvant;
C. be prepared as required dosage form;
D. sterilization, packing.
The preparation that improves osteotrophy of the present invention, calsium supplement are to be the calcium-supplementing preparation that primary raw material is made by calcium carbonate and phosphopeptide caseinate.The calcium source is a calcium carbonate, and among the present invention, the calcium carbonate calcium content is higher, for containing CaCO
3At the chemical compound more than 80%, to take the back and form the absorbent calcium of body with the gastric acid reaction, calcium carbonate is the calsium supplement of using always, by directly replenishing the mode of calcium, reaches the effect of bone density improving; Phosphopeptide caseinate can be resisted the further decomposition of protease, with Ca2
+, Fe2
+Ion has affinity, need not to increase under the condition of vitamin D, can promote the growth of child suffering from rickets's skeleton, and can promote the absorption of calcium.Scientific formulation of the present invention rationally, can realize the effect of bone density improving by directly replenishing calcium, realize promoting calcium absorption, reduce calcium loss, improving bone metabolism and osteotrophy.
The specific embodiment
Explanation under doing into below in conjunction with embodiment to the present invention, but be not limited to embodiment.
Embodiment 1
Calcium carbonate 200g
Phosphopeptide caseinate 20g
Microcrystalline Cellulose 30g
Magnesium stearate 2.5g
Make 1000
Preparation method: with calcium carbonate, phosphopeptide caseinate, microcrystalline Cellulose mix homogeneously, dry granulation, granulate adds the magnesium stearate mixing, tabletting or coating operation bag film-coat routinely, promptly.
Embodiment 2
Calcium carbonate 625g
Phosphopeptide caseinate 20g
30 POVIDONE K 30 BP/USP 30 20g
Microcrystalline Cellulose 100g
Magnesium stearate 2.5g
Make 1000
Preparation method: with calcium carbonate, phosphopeptide caseinate, microcrystalline Cellulose mix homogeneously, make binding agent, the system soft material with 10% 30 POVIDONE K 30 BP/USP, 30 aqueous solutions, granulate 80 ± 10 ℃ of dryings, granulate, add the magnesium stearate mixing, tabletting or coating operation bag film-coat routinely, promptly.
Embodiment 3
Calcium carbonate 1200g
Phosphopeptide caseinate 20g
30 POVIDONE K 30 BP/USP 30 40g
Microcrystalline Cellulose 300g
Magnesium stearate 15g
Make 1000
Preparation method: with calcium carbonate, phosphopeptide caseinate, microcrystalline Cellulose mix homogeneously, make binding agent, the system soft material with 10% 30 POVIDONE K 30 BP/USP, 30 aqueous solutions, granulate 80 ± 10 ℃ of dryings, granulate, add the magnesium stearate mixing, tabletting or coating operation bag film-coat routinely, promptly.
Embodiment 4
Calcium carbonate 650g
Phosphopeptide caseinate 20g
Sucrose 4330g
Make 1000 bags
Preparation method: with the calcium carbonate more than 200 orders, phosphopeptide caseinate mix homogeneously, add the cane sugar powder mixing, make wetting agent with 40% ethanol, the system soft material is granulated, 80 ± 10 ℃ of dryings, and granulate, packing, promptly.
Embodiment 5
Calcium carbonate 800g
Phosphopeptide caseinate 20g
Carboxymethylstach sodium 40g
Magnesium stearate 7g
Make 1000
Preparation method: with calcium carbonate, phosphopeptide caseinate, carboxymethylstach sodium mix homogeneously, dry granulation, granulate adds the magnesium stearate mixing, capsule charge, promptly.
Claims (9)
1, a kind of preparation that improves osteotrophy mainly is to be that primary raw material preparation gets by calcium carbonate, phosphopeptide caseinate, it is characterized in that main raw materials in proportion is: calcium carbonate 10-60 part, 1 part of phosphopeptide caseinate, adjuvant 0.1-250 part.
2, the preparation that improves osteotrophy according to claim 1 is characterized in that, the content of described calcium carbonate is greater than or equal to 80%.
3, the preparation that improves osteotrophy according to claim 1 and 2 is characterized in that, described calcium carbonate be animal shell or the chemical compound that obtains with existing method.
4, the preparation that improves osteotrophy according to claim 1 is characterized in that, described preparation is a kind of in tablet, film coated tablet, capsule, soft capsule, the granule.
5, the preparation that improves osteotrophy according to claim 4 is characterized in that, described adjuvant, the adjuvant of tablet, film coated tablet are microcrystalline Cellulose, 30 POVIDONE K 30 BP/USP 30, magnesium stearate, hypromellose.
6, the preparation that improves osteotrophy according to claim 4 is characterized in that, described adjuvant, the adjuvant of capsule be in starch, microcrystalline Cellulose, carboxymethylstach sodium, magnesium stearate, the Capsules more than two kinds or three kinds.
7, the preparation that improves osteotrophy according to claim 4 is characterized in that, described adjuvant, soft capsule adjuvant are gelatin, glycerol.
8, the preparation that improves osteotrophy according to claim 4 is characterized in that, described adjuvant, the adjuvant of granule are one or two or more kinds in sucrose, mannitol, the aspartame.
9, the preparation that improves osteotrophy according to claim 1 is characterized in that, its preparation method is:
A. under the normal temperature and pressure with calcium carbonate and phosphopeptide caseinate mix homogeneously;
B. add adjuvant;
C. be prepared as required dosage form;
D. sterilization, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100586864A CN101314031A (en) | 2008-07-14 | 2008-07-14 | Preparation for improving osteotrophy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100586864A CN101314031A (en) | 2008-07-14 | 2008-07-14 | Preparation for improving osteotrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101314031A true CN101314031A (en) | 2008-12-03 |
Family
ID=40105276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100586864A Pending CN101314031A (en) | 2008-07-14 | 2008-07-14 | Preparation for improving osteotrophy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101314031A (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010137979A3 (en) * | 2009-05-27 | 2011-04-14 | N.V. Nutricia | Combination of a leucine source and an omega- 3 unsaturated fatty acid source for use in the treatment of hypercaemia |
| CN102552877A (en) * | 2011-12-15 | 2012-07-11 | 广东汤臣倍健生物科技股份有限公司 | Health-care preparation for improving osteoporosis and increasing bone density and preparation method thereof |
| WO2013088440A1 (en) * | 2011-12-13 | 2013-06-20 | Amorphical Ltd. | Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders |
| CN104705658A (en) * | 2015-04-09 | 2015-06-17 | 四川健之源科技有限公司 | Health food with bone density improving function |
| CN104939089A (en) * | 2015-06-24 | 2015-09-30 | 广州施健生物科技有限公司 | Nutrition composite having function of improving bone mineral density and preparation method and application thereof |
| CN106333370A (en) * | 2016-08-19 | 2017-01-18 | 江西中天医药生物有限公司 | Health food prepared from selenium-enriched yeast and calcium carbonate as main raw materials and used for supplementing selenium and calcium for human body |
| CN108543054A (en) * | 2018-05-31 | 2018-09-18 | 广州聚澜健康产业研究院有限公司 | A kind of calcium compensation capsule and preparation method thereof |
| CN109289038A (en) * | 2018-11-21 | 2019-02-01 | 江西维莱营健高科有限公司 | A kind of composition and its preparation method and application |
| US11052107B2 (en) | 2015-06-04 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates |
| US11052108B2 (en) | 2016-10-25 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate for treating a leukemia |
| CN116671638A (en) * | 2023-06-15 | 2023-09-01 | 江西维莱营健高科有限公司 | Casein calcium tablet and preparation method thereof |
| US12357656B2 (en) | 2020-07-23 | 2025-07-15 | Amorphical Ltd | Amorphous calcium carbonate for improving athletic performance |
-
2008
- 2008-07-14 CN CNA2008100586864A patent/CN101314031A/en active Pending
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010137979A3 (en) * | 2009-05-27 | 2011-04-14 | N.V. Nutricia | Combination of a leucine source and an omega- 3 unsaturated fatty acid source for use in the treatment of hypercaemia |
| US9867796B2 (en) | 2009-05-27 | 2018-01-16 | N.V. Nutricia | Combination of a leucine source and an omega-3 unsaturated fatty acid source for use in the treatment of hypercalcaemia |
| US10688124B2 (en) | 2011-12-13 | 2020-06-23 | Amorphical Ltd | Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders |
| WO2013088440A1 (en) * | 2011-12-13 | 2013-06-20 | Amorphical Ltd. | Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders |
| US10064890B2 (en) | 2011-12-13 | 2018-09-04 | Amorphical Ltd. | Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders |
| CN102552877A (en) * | 2011-12-15 | 2012-07-11 | 广东汤臣倍健生物科技股份有限公司 | Health-care preparation for improving osteoporosis and increasing bone density and preparation method thereof |
| CN104705658A (en) * | 2015-04-09 | 2015-06-17 | 四川健之源科技有限公司 | Health food with bone density improving function |
| US12115184B2 (en) | 2015-06-04 | 2024-10-15 | Amorphical Ltd. | Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates |
| US11052107B2 (en) | 2015-06-04 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates |
| CN104939089A (en) * | 2015-06-24 | 2015-09-30 | 广州施健生物科技有限公司 | Nutrition composite having function of improving bone mineral density and preparation method and application thereof |
| CN106333370A (en) * | 2016-08-19 | 2017-01-18 | 江西中天医药生物有限公司 | Health food prepared from selenium-enriched yeast and calcium carbonate as main raw materials and used for supplementing selenium and calcium for human body |
| US11052108B2 (en) | 2016-10-25 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate for treating a leukemia |
| CN108543054A (en) * | 2018-05-31 | 2018-09-18 | 广州聚澜健康产业研究院有限公司 | A kind of calcium compensation capsule and preparation method thereof |
| CN109289038A (en) * | 2018-11-21 | 2019-02-01 | 江西维莱营健高科有限公司 | A kind of composition and its preparation method and application |
| CN109289038B (en) * | 2018-11-21 | 2021-06-15 | 江西维莱营健高科有限公司 | A kind of composition and its preparation method and application |
| US12357656B2 (en) | 2020-07-23 | 2025-07-15 | Amorphical Ltd | Amorphous calcium carbonate for improving athletic performance |
| CN116671638A (en) * | 2023-06-15 | 2023-09-01 | 江西维莱营健高科有限公司 | Casein calcium tablet and preparation method thereof |
| CN116671638B (en) * | 2023-06-15 | 2024-03-22 | 江西维莱营健高科有限公司 | Casein calcium tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101314031A (en) | Preparation for improving osteotrophy | |
| CN101322838A (en) | Formulation for replenishing calcium | |
| CN104688691A (en) | Novel compositions based on gamma-hydroxybutyric acid | |
| CN105456288B (en) | Health-care medicinal preparation for supplementing magnesium and resisting oxidation and preparation method thereof | |
| JP3970941B2 (en) | Methanediphosphonic acid preparations containing ion exchangers | |
| JPH0399016A (en) | Doubly coated granule | |
| CA2162470C (en) | Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as the active substance | |
| CA1314233C (en) | Calcium supplements | |
| CN101091719A (en) | Compound medicinal preparation of proton pump inhibitor and aluminum magnesium carbonate, and preparation method | |
| CN101804030B (en) | Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof | |
| CN1961957A (en) | Anti-aging colon absorption preparation | |
| CN102058878B (en) | Prosoma pellet tablet for generating allicin in stomach and preparation method thereof | |
| CN101716180A (en) | Combined medicament for supplementing zinc and calcium and preparation method thereof | |
| CN101756947A (en) | Compound solid preparation for treating asthma | |
| CN101390844B (en) | Arginine ibuprofen tablet and preparation method thereof | |
| CN101314030A (en) | Preparation for accelerating bone growth | |
| CN103156812A (en) | Dextrorotation ibuprofen dried suspension and preparation method thereof | |
| CN101721387B (en) | Calcium carbonate effervescing agent and preparation method thereof | |
| CN101327316A (en) | Formulation for treating and preventing acalcerosis | |
| CN101797385B (en) | Oral calcium pharmaceutical composition | |
| CN101322836A (en) | Formulation for improving bone metabolism | |
| CN101322835A (en) | Composite type formulation for replenishing calcium | |
| CN101322837A (en) | Formulation for increasing bone density | |
| CN102218072A (en) | Pharmaceutical composition for treating calcium deficiency, and preparation thereof | |
| CN103655574A (en) | Compound ferrous succinate and folic acid composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20081203 |